Skip to Content

Proleukin (aldesleukin) Disease Interactions

There are 12 disease interactions with Proleukin (aldesleukin):

Major

Aldesleukin (Includes Proleukin) ↔ Autoimmune Diseases

Severe Potential Hazard, Moderate plausibility

Applies to: Autoimmune Disorder

Aldesleukin may exacerbate existing or activate quiescent autoimmune disease. Therapy with aldesleukin should be administered cautiously in patients with autoimmune diseases.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Cardiovascular Disease

Severe Potential Hazard, High plausibility

Applies to: Cardiovascular Disease

The use of aldesleukin is contraindicated in patients with abnormal cardiac function as indicated by a thallium stress test. Therapy with aldesleukin should be administered with extreme caution in patients with a normal thallium stress test who have a history of cardiac disease. Close clinical monitoring of cardiac function is required. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced . Subsequent treatment with aldesleukin is contraindicated in patients with sustained ventricular tachycardia, rhythm disturbances uncontrolled or unresponsive to management, recurrent chest pain with ECG changes consistent with angina or myocardial infarction, or pericardial tamponade.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Edema

Severe Potential Hazard, High plausibility

Applies to: Fluid Retention

Aldesleukin can cause Capillary Leak Syndrome resulting in ascites or pulmonary edema. Administration of IV fluids may be necessary to maintain organ perfusion and blood pressure. Aldesleukin should be administered cautiously in patients with fixed fluid requirements and/or those adversely affected by fluid overload.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Hepatic Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Hepatotoxicity such as elevated bilirubin, transaminase and alkaline phosphatase levels have been reported in over 55% of patients administered aldesleukin. Hepatotoxicity is generally reversible, however, hepatic failure resulting in death has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised hepatic function. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Clinical monitoring of hepatic function is recommended.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Hypotension

Severe Potential Hazard, High plausibility

Applies to: Hypotension

Hypotension, primarily associated with capillary leak syndrome, has been reported in 85% of patients administered aldesleukin. Seventy-one percent of patients with hypotension required pressor management. Therapy with aldesleukin should be administered cautiously in patients predisposed to hypotension.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Myelosuppression

Severe Potential Hazard, Moderate plausibility

Applies to: Bone Marrow Depression/Low Blood Counts, Bleeding, Gastrointestinal Perforation

Aldesleukin induces myelosuppression, primarily thrombocytopenia and anemia. Leukopenia has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised bone marrow reserve. Clinical monitoring of hematopoietic function is recommended. Subsequent treatment with aldesleukin is contraindicated in patients requiring surgery for GI bleeding or in those patients with bowel ischemia/perforation.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Neutrophil Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

The use of aldesleukin may be contraindicated in patients with infections, particularly bacterial diseases. Aldesleukin can interfere with neutrophil chemotaxis and increase the risk of disseminated infections, including bacterial endocarditis and sepsis. Therefore, preexisting bacterial infections should be adequately treated prior to initiation of aldesleukin therapy. Close clinical monitoring of hematopoietic function is recommended during therapy. Since there is increasing evidence that neutrophils may also play important roles in viral and other infections, it may be reasonable in some cases to defer aldesleukin treatment in patients with active nonbacterial infections.

References

  1. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  2. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Organ Transplant

Severe Potential Hazard, High plausibility

Applies to: Organ Transplant

The use of aldesleukin is contraindicated in patients with allograft organ transplants. Aldesleukin possesses immunoregulatory properties that may increase the risk of organ rejection, including enhancement of lymphocyte mitogenesis and cytotoxicity and induction of killer cell activity.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Pulmonary Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Pulmonary Impairment

The use of aldesleukin should be restricted to patients with adequate ventilatory function (baseline FEV1 > 2 L or >= 75% of the predicted value based on height and age). Extreme caution should be used in treating patients with normal test results but have a history of pulmonary disease. Pulmonary congestion and dyspnea have been reported in over 50% of patients receiving the recommended dosage of aldesleukin. Respiratory adverse effects are often associated with the capillary leak syndrome induced by aldesleukin and may also include pulmonary edema, respiratory failure requiring intubation, tachypnea, pleural effusion, wheezing, apnea, pneumothorax, hemoptysis, respiratory arrest, and pulmonary emboli. During therapy, pulmonary function should be monitored regularly by clinical examination, assessment of vital signs and pulse oximetry, and arterial blood gas determinations as needed. When toxicities occur that require a dosage modification, doses should be withheld rather than reduced. Subsequent treatment with aldesleukin is contraindicated in patients who develop respiratory failure requiring intubation for longer than 72 hours.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Renal toxicity such as oliguria/anuria and elevated BUN and serum creatinine has been reported in > 60% of patients during aldesleukin therapy. Renal toxicity is generally reversible, however, patients with renal impairment are at increased risk for more severe and prolonged renal dysfunction. Therapy with aldesleukin should be administered cautiously in patients with compromised renal function. Clinical monitoring of renal function is recommended. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Subsequent treatment with aldesleukin is contraindicated in patients experiencing renal dysfunction that requires greater than seventy-two hours of dialysis.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Major

Aldesleukin (Includes Proleukin) ↔ Seizures

Severe Potential Hazard, High plausibility

Applies to: Seizures

Aldesleukin can induce seizures. Therapy with aldesleukin should be administered with extreme caution in patients with or predisposition to seizure disorders. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced . Subsequent treatment with aldesleukin is contraindicated in patients with repetitive or difficult to control seizures.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.
Moderate

Aldesleukin (Includes Proleukin) ↔ Mental Status Changes

Moderate Potential Hazard, High plausibility

Applies to: Depression, Psychosis

Mental status changes such as lethargy, somnolence, depression, confusion or agitation were reported in over 70% of patients administered aldesleukin. Therapy with aldesleukin should be administered cautiously to patients with or predisposition to altered mental status. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Clinical monitoring of mental status is recommended.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.

Proleukin (aldesleukin) drug Interactions

There are 759 drug interactions with Proleukin (aldesleukin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide